Name of the Company PHARMAIDS PHARMACEUTICALS LIMITED Statement of Profit and Loss for the period ended 30th September, 2017

II Other Income 0.40 - - 0.40 0.04 11.1 III Total Income (I+1) 5.30 19.58 31.13 24.88 65.42 121.2 IV EXPENSES -		Particulars	No.	Unaudited 30.09.2017	Audited 30.06.2017	Off. Ended Unaudited 30.09.2016	Year to date figures for current period ended 30.9.2017	Year to date figures for previous period ended 30.9.2016	Audited 31.03.2017
III Total Lacone (1+10) 5.30 19.58 31.13 24.88 65.42 121.1 IVE EXPENSES	I	Revenue From Operations		4.90	19.58	31.18	24.48	65.38	120.25
IV EXPENSES Image: second sec	II	Other Income		0.40	-	-	0.40	0.04	1.01
Cost of materials consumed - 2.67 1.29 2.67 4.48 64.4 Parchases of Stock-in-Trade 4.50 2.63 14.41 7.13 24.64 - Changes in inventories of finished goods, Stock-in -Trade and work-in-progress (0.52) 21.19 (0.73) 20.67 7.22 2.2 Employee benefits expense 1.62 3.51 5.48 5.13 111.46 164. Percention and amorization expense 0.02 - 1.96 0.02 3.92 6. Other expenses 6.88 7.88 12.09 14.86 17.50 70.07 Total expenses 12.53 38.00 35.98 50.63 72.07 164. V Profit/(loss) before texpenses 14.82 (4.80) (25.65) (6.65) 8. VII Profit/(loss) for the period from (tax (III-V) (7.23) (18.42) (4.80) (27.40) (6.65) 10. VII Profit/(loss) for the period form (continuing operations) - - - -	III	Total Income (I+II)		.5.30	19.58	31.13	24.88	65.42	121.26
Purchases of Stock-in-Trade 4.60 2.63 14.41 7.13 24.64 Changes in inventories of finished goods, Stock-in Trade and work-in-progress (0.52) 21.19 (0.73) 20.67 7.22 23 Employee bacefits expense 1.62 3.51 5.48 5.13 11.46 164 Primare costs 0.03 0.02 1.48 0.05 2.85 44. Depreciation and amortization expense 0.02 1.48 0.05 2.85 44. Very relation and amortization expenses (IV) 12.53 38.00 35.98 50.53 77.20 164. V Exceptional Items (IR.42) (4.80) (25.65) (6.65) (43.7) VI Exceptional Items (IR.42) (4.80) (27.40) (6.65) 10. (ID Current fax Adj of cartier year 1.75 - 1.75 - (2) Defered tax -	IV	EXPENSES							
Purchases of Stock-in-Trade 4.60 2.63 14.41 7.13 24.64 Changes in inventories of finished goods, Stock-in Trade and work-in-progress (0.52) 21.19 (0.73) 20.67 7.22 23 Employee bacefits expense 1.62 3.51 5.48 5.13 11.46 164 Primare costs 0.03 0.02 1.48 0.05 2.85 44. Depreciation and amortization expense 0.02 1.48 0.05 2.85 44. Very relation and amortization expenses (IV) 12.53 38.00 35.98 50.53 77.20 164. V Exceptional Items (IR.42) (4.80) (25.65) (6.65) (43.7) VI Exceptional Items (IR.42) (4.80) (27.40) (6.65) 10. (ID Current fax Adj of cartier year 1.75 - 1.75 - (2) Defered tax -		Cost of materials consumed		-	2.67	1.29	2.67	4.48	64.49
Stock in -Trade and work-in-progress Image: Control of the sequence of		Purchases of Stock-in-Trade		4.50	and the second se	14.41		24.64	
Finance costs 0.03 0.02 1.48 0.05 2.85 4.1 Depreciation and amorization expense 0.02 - 1.96 0.02 3.92 6. Other expenses 0.88 7.88 12.09 14.86 17.50 70.07 Iter expenses 10.12 53 38.00 35.98 50.53 72.07 164.31 V Profit(loss) before exceptional items and tax (III-IV) (7.23) (18.42) (4.80) (25.65) (6.65) (4.7) VII Exceptional Items * - - - - 51. VIII Textificity optimics (7.23) (18.42) (4.80) (25.65) (6.65) 8. VIII Textificity optimics - - - - - (2) - - - - (2) - - - - - - - - - - - - - - - - -				(0.52)	21.19	(0.73)	20.67	7.22	2.95
Depreciation and amortization expense 0.02 - 1.96 0.02 3.92 6.3 Other expenses 6.88 7.98 12.09 14.86 17.50 70.0 V Profit/(loss) before exceptional items and use i		Employee benefits expense		1.62	3.51	5.48	5.13	11.46	16.63
Other expenses 6.88 7.98 12.09 14.86 17.50 70.1 Total expenses Total expenses (12.53 38.00 35.98 50.53 72.07 164.4 V Profit/(loss) before exceptional items and tax (11.1V) (7.23) (18.42) (4.80) (25.65) (6.65) (43.7) VI Exceptional Items - - - - 51.1 VIT Profit/0ss) before tax (V+VI) (7.23) (18.42) (4.80) (25.65) (6.65) 8. VIII Profit/0ss) before tax (V+VI) (7.23) (18.42) (4.80) (27.40) (6.65) 10. (2) Deferred tax - - - - - (2.2) (2.7.40) (6.65) 10. (2.1.65) (0.1.65) 10. (2.1.65) (2.1.65) 10. (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65) (2.1.65)		Finance costs		0.03	0.02	1.48	0.05	2.85	4.01
Total expenses (IV) 12.53 38.00 35.98 50.53 72.07 164.1 V Profit/(loss) before exceptional items and tax (III-IV) (7.23) (18.42) (4.80) (25.65) (6.65) (43.7) VI Exceptional Items - - - 51.1 VII Total Comprehensity (7.23) (18.42) (4.80) (25.65) (6.65) 88. VII Exceptional Items - - - - 51.1 VIII Tax caperse: - <td></td> <td>Depreciation and amortization expense</td> <td></td> <td>0.02</td> <td>-</td> <td></td> <td>0.02</td> <td>3.92</td> <td>6.37</td>		Depreciation and amortization expense		0.02	-		0.02	3.92	6.37
V Profit/(loss) before exceptional items and tax (III-IV) (7.23) (18.42) (4.80) (25.65) (6.65) (43.7) VI. Exceptional items - - - 51.1 VI. Exceptional items - - - 51.1 VI. Tax expense: - - - - - (1) Current tax Adj. of earlier year 1.75 -				A start the second s		and the second se		and the second data was a second data where the second data was a second data was	70.53
tax (III-IV) - - - - - 51.1 VII Exceptional Items (7.23) (18.42) (4.80) (25.65) (6.65) 8. VIII Tax expense: - - - 1.75 -							and the second se		164.98
VII Profit(loss) before tax (V+VI) (7.23) (18.42) (4.80) (25.65) (6.65) 8. VIII Tax expense: - - 1.75 - <td< td=""><td>V</td><td></td><td></td><td>(7.23)</td><td>(18.42)</td><td>(4.80)</td><td>(25.65)</td><td>(6.65)</td><td>(43.72)</td></td<>	V			(7.23)	(18.42)	(4.80)	(25.65)	(6.65)	(43.72)
VIII Tax expease: 1.75 1.75 - - (1) Current tax Adj. of earlier year 1.75 -<	VI	Exceptional tients					-	-	51.97
(1) Current tax Adj. of earlier year 1.75 - - 1.75 - - - 1.75 - - (2) 1X Profit (Loss) for the period from continuing operations (VII-VIII) (8.98) (18.42) (4.80) (27.40) (6.65) 10. X Profit (Loss) form biscontinued operations - <t< td=""><td></td><td></td><td></td><td>(7.23)</td><td>(18.42)</td><td>(4.80)</td><td>(25.65)</td><td>(6.65)</td><td>8.25</td></t<>				(7.23)	(18.42)	(4.80)	(25.65)	(6.65)	8.25
(2) Deferred tax - - - - - - (2. IX Profit (Loss) for the period from continuing operations (VII-VIII) (8.98) (18.42) (4.80) (27.40) (6.65) 10. X Profit (Loss) from discontinued operations -	VIII	-	2.1.2	1 75		-	1.75	- 1	
IX Profit (Loss) for the period from continuing operations (VII-VIII) (8.98) (18.42) (4.80) (27.40) (6.65) 10. X Profit/(loss) from discontinued operations -				-	-	-	-	-	(2.72)
X Profit/(loss) from discontinued operations -<	IX	Profit (Loss) for the period from		(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
XII Profit/(loss) from Discontinued operations (after tax) (X-XI)	X	Profit/(loss) from discontinued operations		-	-			-	-
XII Profit/(loss) from Discontinued operations (after tax) (X-XI) - <t< td=""><td>XI</td><td>Tax expense of discontinued operations</td><td></td><td>-</td><td>-</td><td></td><td>1.0.0</td><td></td><td>-</td></t<>	XI	Tax expense of discontinued operations		-	-		1.0.0		-
X1II Profit/(loss) for the period (IX+XII) (8.98) (18.42) (4.80) (27.40) (6.65) 10. XIV Other Comprehensive Income - <	XII						-	-	
XIV Other Comprehensive Income - <td< td=""><td>XIII</td><td>-</td><td></td><td>(8.98)</td><td>(18.42)</td><td>(4.80)</td><td>(27.40)</td><td>(6.65)</td><td>10.97</td></td<>	XIII	-		(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
profit or lossImage: Constraint of the sector o	XIV	Other Comprehensive Income		-	-	-	-	-	
not be reclassified to profit or loss Image: Constrained State	1			-	-	-	-	Ī	
profit or lossImage: constraint of the sectassified to profit or lossImage: constraint of the sectas se					-	-	-		
(a) Income tax relating to items that with be reclassified to profit or loss Image: Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period) Image: Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period) Image: Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period) Image: Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period) Image: Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period) Image: Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period (0.26) (0.54) (0.14) (0.80) (0.20) (0.20) XVI Earnings per equity share (for continuing operation): Image: Comprehensive Income for the period (0.26) (0.54) (0.14) (0.80) (0.20					-	-	-	-	
XV Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period) - </td <td></td> <td></td> <td></td> <td>in an an</td> <td>-</td> <td>-</td> <td></td> <td>-</td> <td>-</td>				in an	-	-		-	-
XVI Earnings per equity share (for continuing operation): -	XV	period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income							-
(1) Basic (0.20) (0.01) (0.01) (0.00) (0.20) (0.20) (2) Diluted (0.26) (0.54) (0.14) (0.80) (0.20) (0.20) XVII Earnings per equity share (for discontinued operation): 1	XVI		5		-	1			-
(2) Diluted (0.20) (0.01) (0.01) (0.01) (0.01) XVII Earnings per equity share (for discontinued operation): 1 1 1 (1) Basic 1 1 1 1 (2) Diluted 1 1 1 1 XVII Earnings per equity share(for discontinued & continuing operations) 1 1 1		(1) Basic							0.32
discontinued operation): Image: Constraint operation Image: Constraint opera				(0.26)	(0.54)	(0.14)) (0.80) (0.20)	0.32
(2) Diluted Image: Constraint of the second secon	XVI	discontinued operation):		and a second			4		
I discontinued & continuing operations)		(2) Diluted							
(1) Basic		discontinued & continuing operations)	or						
				-	da Dharme	ceuticals L	inited		



1. The above results have been reviewed by the Audit Committee and approved by the board of ${\sf U}$ held on 15th November, 2017. 2. The Un-Audited Financial Results for the Quarter ended 30th Sept, 2017 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013 3. The figures of the previous year/periods have been re-grouped/reclassifed, whenever necessary, for the purpose of comparison. 4) The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only 5) Provision for Income Tax and Deffered Tax will be made at the end of the Financial year.

Reconciliation between net profit or loss reported in accordance with Indian GAAP (previous GAAP) and Ind AS for the quarter ended 30 June 2017 and year ended 31 March 2017 is as follows: Veenended

	Quarter Ended			Six months Ended		Year ended
	30.09.2017		30.09.2016	30.09.2017	30.09.2016	31.03.2017
Falliculais		The second se	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Net profit reported for the quarter earlier as per the	(8.98)	States and States		(27.40)	(6.65)	10.97
Net profit for the period as per Ind AS	(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
Other Comprehensive Income	-	-	· · -	- 1	-	-
Total Comprehensive Income for the period as per	(8.98)	(18.42)	(4.80)	(27.40)	(6.65)	10.97
Ind AS	A State of the second second		- DILADA	ATOC DUADMACEL	TICALS LIMITED	

For PHARMAIDS PHARMACEUTICALS LIMITED For Pharmaids PAtron and Cats third

DR. GHISULAL JAIN

Managing Director Managing Director

meeting

Place : Hyderabad

Date: 15-11-2017 Mde om Nepm

RAKETH S JAIN & AS FOU CHARTERED ACCOUNT

B. Rough Ke (B. RAME PARTNER M.No: 200304

Sheet as at 30th September 2017		Figures as at the	Figures as	at the
	Note	end of		
Particulars	No.	30.09.2017	end of 31.0	3.201
1	2	3	4	
1 ASSETS				
Non-current assets	-	0.31		
(a) Property, Plant and Equipment		0.51		
(b) Capital work-in-progress		-		
(c) Investment Property		-		
(d) Goodwill		-		
(e) Other Intangible assets		-		
(f) Intangible assets under development		10000000		
(g) Biological Assets other than bearer plants		-		
(h) Financial Assets				
(<i>i</i>) Investments		-		
(<i>ii</i>) Trade receivables		-		
(<i>iii</i>) Loans		-		
(<i>iv</i>) Others (to be specified)				
(<i>i</i>) Deferred tax assets (net)				37.9
(<i>i</i>) Deterior data about (<i>i</i> -) (<i>j</i>) Other non-current assets		34.67		51.
2 Current assets				24.
(a) Inventories		1.13	2	24.
(b) Financial Assets				
(<i>i</i>) Investments				70
(<i>i</i>) Trade receivables		62.3	Contraction of the second	78. 8.
(<i>iii</i>) Cash and cash equivalents		19.2	* · · · · · · · · · · · · · · · · · · ·	
(iv) Bank balances other than (iii) above		33.3	8	52
(v) Loans				
(v) Loans (vi) Others (to be specified)	1 Parti			te i le
(c) Current Tax Assets (Net)				
(d) Other current assets Total As	sets	151.1	14	202
EQUITY AND LIABILITIES Equity				336
(a) Equity Share capital		336.		(193
(b) Other Equity		(220.)	93)	(13
LIABILITIES				
1 Non-current liabilities				
(a) Financial Liabilities			~	
(<i>i</i>) Borrowings		9.	26	
(<i>ii</i>) Trade payables				
(<i>iii</i>) Other financial liabilities (other than the	nose			
specified in item (b), to be specified)				
(b) Provisions			-	
(c) Deferred tax liabilities (Net)				
(d) Other non-current liabilities				
2 Current liabilities				
(a) Financial Liabilities		2	2.65	
(<i>i</i>) Borrowings		23	3.24	4
(<i>ii</i>) Trade payables	those	1.		
(iii) Other financial liabilities (other than	mose	and the second		
specified in item (c)	1000			

RAKESH S JAIN & ASSOCIATES

CA

B. Ramesh Kumar (Mob) : +91-9849025641 E-mail : rsjainassociates@rediffmail.com

> 14-6-191, Nagar Khana, Begum Bazar, Hyderabad - 500 012. (T.S.) INDIA.

> > Date :

LIMITED REVIEW REPORT

To The Board of Directors, M/s Pharmaids Pharmaceuticals Limited, Hyderabad.

CHARTERED ACCOUNTANTS

We have reviewed the accompanying statement of unaudited financial results of **Pharmaids Pharmaceuticals Limited** for the Quarter ended 30th September, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Management has informed to us being quarterly closing, the company has not accounted for taxes on income i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end.

Based on our review conducted as above and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations,2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For RAKESH S. JAIN AND ASSOCIATES Chartered Accountants Firm Registration No. 010129S

ERED ACCO

B. Rauch Kit

B RAMESH KUMAR

Partner

M. No. 200304

Date: 15-11-2017 Place: Hyderabad.